Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) (“Aoxing Pharma”), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, on 14 May 2014 announced its financial and operational results for the three and nine month periods ended March 31, 2014. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on May 14, 2014. Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) stock performance was 17.86% in last session and finished the day at $0.330. Traded volume was 114,975.00million shares in the last session and the average volume of the stock remained 42.39K shares. The beta of the stock remained 2.09. Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN) insider ownership is 44.95%.

Hyperion Therapeutics, Inc. (NASDAQ:HPTX) on 03 June 2014 announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Standard review in Canada takes 18 months or more and Priority Review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review time to approximately six months. Hyperion Therapeutics Inc (NASDAQ:HPTX) dropped -9.41 percent to $26.95 Friday on volume of 328,217.00million shares. The intra-day range of the stock was $26.31 to $29.25. Hyperion Therapeutics Inc (NASDAQ:HPTX) has a market capitalization of $546.12million.

Aerie Pharmaceuticals Inc (NASDAQ:AERI) major shareholder Iv L.P. Acp sold 300,000 shares of Aerie Pharmaceuticals stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $16.00, for a total value of $4,800,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission. Aerie Pharmaceuticals Inc (NASDAQ:AERI)’s stock on June 06, 2014 reported a increase of 5.71% to the closing price of $16.49. Its fifty two weeks range is $10.25 -$27.15. The total market capitalization recorded $386.48million. The overall volume in the last trading session was 357,489.00million shares. In its share capital, AERI has 23.44million outstanding shares.

Fibrocell Science Inc (NASDAQ:FCSC) major shareholder Randal J. Kirk bought 400,000 shares of the stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average cost of $2.90 per share, with a total value of $1,160,000.00. On Friday, shares of Fibrocell Science Inc (NYSEMKT:FCSC) advanced 14.38% to close the day at $3.34. Company return on investment (ROI) is -47.10% and its monthly performance is recorded as 9.15%. Fibrocell Science Inc (NYSEMKT:FCSC) quarterly revenue growth is -40.99%.

Abaxis Inc (NASDAQ:ABAX) Director Richard Bastiani sold 4,000 shares of the company’s stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $41.88, for a total value of $167,520.00. Following the completion of the sale, the director now directly owns 49,400 shares in the company, valued at approximately $2,068,872. Abaxis Inc (NASDAQ:ABAX) stock performance was 3.32% in last session and finished the day at $43.54. Traded volume was 448,120.00million shares in the last session and the average volume of the stock remained 142.62K shares. The beta of the stock remained 1.13. Abaxis Inc (NASDAQ:ABAX) insider ownership is 6.10%.